Cognition Therapeutics, Inc. CGTX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
21/100
Weak

Ranked against 712 peers in Biotechnology

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical … Full CGTX analysis →

Key risks

  • ROIC Below WACC or Peers ROIC at 22.4th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.08), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CGTX ranks in Biotechnology

Cognition Therapeutics, Inc. ranks #596 of 713 scored companies in Biotechnology by moat score — the top 84%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
592 Revelation Biosciences, Inc. REVB 22/100 Weak
593 Klotho Neurosciences, Inc. KLTOW 21/100 Weak
594 Revelation Biosciences, Inc. REVBW 21/100 Weak
595 Synlogic, Inc. SYBX 21/100 Weak
596 Cognition Therapeutics, Inc. CGTX 21/100 Weak
597 Impact BioMedical, Inc. IBO 21/100 Weak
598 HCW Biologics Inc. HCWB 21/100 Weak
599 Mustang Bio, Inc. MBIO 21/100 Weak
600 Allarity Therapeutics, Inc. ALLR 21/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How CGTX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 22 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 20 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CGTX's moat

What is Cognition Therapeutics, Inc.'s moat score?

Cognition Therapeutics, Inc. (CGTX) scores 21 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #596 of 713 scored companies in Biotechnology, the top 84%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (22/100) and its weakest is Resilience (20/100).

How does Cognition Therapeutics, Inc. compare with other Biotechnology companies?

Cognition Therapeutics, Inc. ranks #596 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Synlogic, Inc. (SYBX) at 21 just above it and Impact BioMedical, Inc. (IBO) at 21 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Cognition Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Cognition Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and CGTX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (22), Resilience (20), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000